Cat. No.: HY-119182

Mitonafide

(Synonyms: NSC 300288)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia.

For research use only. We do not sell to patients.

Purity: 99.73%
CAS No.: 54824-17-8
Formula: C₁₆H₁₅N₃O₄
Molecular Weight:313.31

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Mitonafide Chemical Structure

CAS No.: 54824-17-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

DNA and RNA synthesis^[1]

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	5.22 μM Compound: Mitonafide	Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
A-375	IC₅₀	5.3 μM Compound: B1	Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]
A549	GI₅₀	65 nM Compound: Mitonafide	Concentration required to inhibit human small cell lung cancer A549 cell growth by 50% after 120 hours; determined by MTT assay Concentration required to inhibit human small cell lung cancer A549 cell growth by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
A549	IC₅₀	0.012 μM Compound: Mitonafide	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 33109400]
A549	IC₅₀	1.5 μM Compound: MAF	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth Antiproliferative activity against human A549 cells assessed as inhibition of cell growth	[PMID: 37974948]
A549	IC₅₀	2.4 μM Compound: 3	Antiproliferative activity against A549 cells after 72 hrs by MTT assay Antiproliferative activity against A549 cells after 72 hrs by MTT assay	[PMID: 17658777]
A549	IC₅₀	3.6 μM Compound: Mitonafide	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
A549	IC₅₀	7.94 μM Compound: Mitonafide	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
CHL-1	IC₅₀	0.5 μM Compound: Mitonafide	Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 72 hrs by MTT assay Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 72 hrs by MTT assay	[PMID: 28458134]
CHL-1	IC₅₀	0.9 μM Compound: Mitonafide	Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 48 hrs by MTT assay Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 48 hrs by MTT assay	[PMID: 28458134]
CHL-1	IC₅₀	2.8 μM Compound: Mitonafide	Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 24 hrs by MTT assay Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 24 hrs by MTT assay	[PMID: 28458134]
CNE-2	IC₅₀	3.42 μM Compound: Mitonafide	Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
HCT-116	GI₅₀	250 nM Compound: Mitonafide	Concentration required to inhibit the growth of human colon cancer HCT116 cell line by 50% to initial after 120 hours; determined using MTT assay Concentration required to inhibit the growth of human colon cancer HCT116 cell line by 50% to initial after 120 hours; determined using MTT assay	[PMID: 15974599]
HCT-116	IC₅₀	12.23 μM Compound: Mitonafide	Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
HCT-15	IC₅₀	2.6 μM Compound: 3	Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay	[PMID: 17658777]
HepG2	IC₅₀	0.012 μM Compound: Mitonafide	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
HepG2	IC₅₀	10.88 μM Compound: Mitonafide	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
HK-2	IC₅₀	2.13 μM Compound: Mitonafide	Cytotoxicity against HK-2 cells incubated for 48 hrs by MTT assay Cytotoxicity against HK-2 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
HL-60	GI₅₀	45 nM Compound: Mitonafide	Concentration required to inhibit the growth of human leukemia cancer HL-60 cell line by 50% after 120 hours; determined by MTT assay Concentration required to inhibit the growth of human leukemia cancer HL-60 cell line by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
HL-60	IC₅₀	1.6 μM Compound: Mitonafide	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 19954251]
Hs 683	IC₅₀	3.7 μM Compound: 3	Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay	[PMID: 17658777]
HT-29	IC₅₀	0.22 μM Compound: 4a	Cytotoxicity against human HT-29 cells after 144 hrs Cytotoxicity against human HT-29 cells after 144 hrs	[PMID: 18774722]
HT-29	IC₅₀	0.6 μM Compound: Mitonafide	In vitro cytotoxicity against HT-29 (human colon adenocarcinoma) cell line. In vitro cytotoxicity against HT-29 (human colon adenocarcinoma) cell line.	[PMID: 9046334]
HUVEC	IC₅₀	5.9 μM Compound: Mitonafide	Cytotoxicity against HUVEC cells incubated for 48 hrs by MTT assay Cytotoxicity against HUVEC cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
L02	IC₅₀	8.51 μM Compound: Mitonafide	Cytotoxicity against human HL7702 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
LoVo	IC₅₀	0.4 μM Compound: 3	Antiproliferative activity against LoVo cells after 72 hrs by MTT assay Antiproliferative activity against LoVo cells after 72 hrs by MTT assay	[PMID: 17658777]
MCF7	GI₅₀	245 nM Compound: Mitonafide	Concentration required to inhibit the growth of human breast cancer MCF-7 cell line by 50% after 120 hours; determined by MTT assay Concentration required to inhibit the growth of human breast cancer MCF-7 cell line by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
MDA-MB-231	IC₅₀	7.59 μM Compound: Mitonafide	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
MGC-803	IC₅₀	3.32 μM Compound: Mitonafide	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
MGC-803	IC₅₀	6.8 μM Compound: Mitonafide	Antiproliferative activity against human MGC-803 cells by MTT assay Antiproliferative activity against human MGC-803 cells by MTT assay	[PMID: 33109400]
MGC-803	IC₅₀	6.81 μM Compound: Mitonafide	Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
MGC-803	IC₅₀	6.81 μM Compound: Mitonafide	Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
NB-4	IC₅₀	3.4 μM Compound: MAF	Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth	[PMID: 37974948]
PC-3	GI₅₀	0.15 μM Compound: MIT	Cytotoxicity against PC3 cells by SRB assay after 48 hrs Cytotoxicity against PC3 cells by SRB assay after 48 hrs	[PMID: 17125272]
SK-MEL-2	GI₅₀	150 nM Compound: Mitonafide	Concentration required to inhibit the growth of human malenoma cancer SK-MEL-2 cell line by 50% after 120 hours; determined by MTT assay Concentration required to inhibit the growth of human malenoma cancer SK-MEL-2 cell line by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
SK-OV-3	IC₅₀	1.38 μM Compound: Mitonafide	Antiproliferative activity against human SK-OV-3 cells by MTT assay Antiproliferative activity against human SK-OV-3 cells by MTT assay	[PMID: 33109400]
SK-OV-3	IC₅₀	1.38 μM Compound: Mitonafide	Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
SK-OV-3	IC₅₀	6.26 μM Compound: Mitonafide	Antiproliferative activity against human SKOV3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
SMMC-7721	IC₅₀	3.22 μM Compound: Mitonafide	Antiproliferative activity against human SMMC-7721 cells by MTT assay Antiproliferative activity against human SMMC-7721 cells by MTT assay	[PMID: 33109400]
SMMC-7721	IC₅₀	6.94 μM Compound: Mitonafide	Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
T-24	IC₅₀	0.012 μM Compound: Mitonafide	Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
T-24	IC₅₀	1.11 μM Compound: Mitonafide	Antiproliferative activity against human T-24 cells by MTT assay Antiproliferative activity against human T-24 cells by MTT assay	[PMID: 33109400]
T-24	IC₅₀	1.11 μM Compound: Mitonafide	Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human T24 cells incubated for 48 hrs by MTT assay	[PMID: 37972528]
T-24	IC₅₀	3.25 μM Compound: Mitonafide	Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
T-24	IC₅₀	5.01 μM Compound: Mitonafide	Antiproliferative activity against human T24 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
U-251	IC₅₀	9.68 μM Compound: Mitonafide	Antiproliferative activity against human U-251 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U-251 cells incubated for 48 hrs by MTT assay	[PMID: 38784471]
U-373MG ATCC	IC₅₀	1.3 μM Compound: 3	Antiproliferative activity against U373MG cells after 72 hrs by MTT assay Antiproliferative activity against U373MG cells after 72 hrs by MTT assay	[PMID: 17658777]
UACC-903	IC₅₀	0.5 μM Compound: Mitonafide	Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 72 hrs by MTT assay	[PMID: 28458134]
UACC-903	IC₅₀	0.8 μM Compound: Mitonafide	Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 48 hrs by MTT assay	[PMID: 28458134]
UACC-903	IC₅₀	11.4 μM Compound: Mitonafide	Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 24 hrs by MTT assay	[PMID: 28458134]
V79	IC₅₀	41.6 μM Compound: B1	Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]

In Vitro

Mitonafide inhibits DNA and RNA synthesis and induces single-strand breaks in the DNA of chinese hamster ovary cells^[1].
The incubation of Mitonafide with rat liver microsomes and NADPH under anaerobic conditions results in the formation of a metabolite identified as 5-aminomitonafide^[2].
Mitonafide (25, 50 μM, 1 h) induces single-stand breaks in the DNA of L1210 cells^[2].
Mitonafide (10-100 μM) exhibits cytotoxic effect in the HOP-62 lung cell line^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[6]

Cell Line:

SK-OV-3, HepG2, A-549, T-24, SMMC-7721, HL-7702
Concentration:

0-100 μM respectively.
Incubation Time:

48 h
Result:

Inhibited cell viability with IC₅₀ values of 6.26, 10.88, 7.94, 5.01, 6.94, 8.51 μM.

In Vivo

Mitonafide (0.5 and 1 mg/kg, i.p., 1-7 days) shows antitumoral potency in S-180 bearing mice^[4].
Mitonafide (5 mg/kg, i.p., twice a day) shows anticancer activity in HepG2 xenograft model^[6].
Mitonafide (single i.p. injection, S-180 bearing mice) shows the LD₅₀ value of 10.0 mg/kg^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

S-180 bearing mice^[4]
Dosage:

0.5 mg/kg and 1 mg/kg
Administration:

Intraperitoneal injection (i.p.) for 1-7 days
Result:

Increased in median survival times.

Animal Model:

HepG2 xenograft model ^[6]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection (i.p.), twice a day.
Result:

Exhibited a relative tumor increment rates (T/C) value of 28.8%.

Chemical Information

CAS No. 54824-17-8
Appearance Solid
Molecular Weight 313.31
Formula C₁₆H₁₅N₃O₄
Color Light yellow to yellow
SMILES

O=C1N(C(C2=CC([N+]([O-])=O)=CC3=CC=CC1=C23)=O)CCN(C)C
Synonyms

NSC 300288
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Pharmaceutics

Benzofuran-Annulated Naphthalimides Trigger Replication Stress, DNA Damage, and p53-Dependent Cell Cycle Arrest. [Abstract]

2026 Jun 20;18(6):754. PMID: 42357370
Pharmaceutics

Benzodioxin-Annulated Naphthalimides as Potent DNA Replication Stress Inducers with Dual p53-Dependent and Independent Antitumor Activity. [Abstract]

2026 Jan 27;18(2):167. PMID: 41754909
C R Acad Bulg Sci

2025 Dec 23.

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL (199.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1917 mL

15.9586 mL

31.9173 mL

5 mM

0.6383 mL

3.1917 mL

6.3835 mL

10 mM

0.3192 mL

1.5959 mL

3.1917 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Llombart M, et al. Phase I study of mitonafide in solid tumors. Invest New Drugs. 1992 Aug;10(3):177-81. [Content Brief]

[2]. inha BK, et al. Mechanism of DNA strand breaks by mitonafide, an imide derivative of 3-nitro-1,8-naphthalic acid. Biochem Pharmacol. 1985 Nov 1;34(21):3845-52. [Content Brief]

[3]. Rosell R, et al. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer. Invest New Drugs. 1992 Aug;10(3):171-5. [Content Brief]

[4]. Samanta S, et al. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent. J Exp Ther Oncol. 2005;5(1):15-22. [Content Brief]

[5]. Pain A, et al. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent. J Exp Clin Cancer Res. 2003 Sep;22(3):411-8. [Content Brief]

[6]. Xin M, et al. Design, synthesis and biological evaluation of 3-nitro-1,8-naphthalimides as potential antitumor agents. Bioorg Med Chem Lett. 2020 Apr 15;30(8):127051. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1917 mL	15.9586 mL	31.9173 mL	79.7932 mL
	5 mM	0.6383 mL	3.1917 mL	6.3835 mL	15.9586 mL
	10 mM	0.3192 mL	1.5959 mL	3.1917 mL	7.9793 mL
	15 mM	0.2128 mL	1.0639 mL	2.1278 mL	5.3195 mL
	20 mM	0.1596 mL	0.7979 mL	1.5959 mL	3.9897 mL
	25 mM	0.1277 mL	0.6383 mL	1.2767 mL	3.1917 mL
	30 mM	0.1064 mL	0.5320 mL	1.0639 mL	2.6598 mL
	40 mM	0.0798 mL	0.3990 mL	0.7979 mL	1.9948 mL
	50 mM	0.0638 mL	0.3192 mL	0.6383 mL	1.5959 mL
	60 mM	0.0532 mL	0.2660 mL	0.5320 mL	1.3299 mL
	80 mM	0.0399 mL	0.1995 mL	0.3990 mL	0.9974 mL
	100 mM	0.0319 mL	0.1596 mL	0.3192 mL	0.7979 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Mitonafide

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Mitonafide

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Mitonafide

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Mitonafide

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Mitonafide Related Classifications

Cat. No.: HY-119182